Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

14.3%

2 terminated out of 14 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (1)
P 1 (2)
P 2 (4)
P 3 (1)
P 4 (1)

Trial Status

Completed8
Active Not Recruiting2
Terminated2
Withdrawn1
Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04769167Not ApplicableCompleted

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

NCT06149494Phase 2Completed

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

NCT06922474Active Not RecruitingPrimary

Molecular Epidemiology of Enteroviruses Detected at the Virology Laboratory of Brest University Hospital During the Period 2018-2024: Retrospective Analysis of an Atypical Meningitis Epidemic in 2024 (BrEcho9Men)

NCT04431050Terminated

Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens

NCT05099029Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

NCT06263439Recruiting

Surveillance of HFMD in Pediatric Outpatients

NCT04535648WithdrawnPrimary

Detection of Enterovirus Genotypes by CRISPR Technology

NCT04091880Phase 4CompletedPrimary

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

NCT05016687Phase 1Completed

First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.

NCT03268083Phase 2CompletedPrimary

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

NCT01129232Phase 2Terminated

Diabetes Virus Detection Project, Intervention With GAD-alum

NCT02777411Phase 2CompletedPrimary

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

NCT01313715Phase 1Completed

A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

NCT00426699CompletedPrimary

Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection

Showing all 14 trials

Research Network

Activity Timeline